RemeGen registers Phase II/III study of RC118 plus RC148 for claudin 18.2-positive gastric cancer
The study, led by RemeGen Co., Ltd., plans to enroll 680 participants and plans to start in November 2026, with primary completion projected for April 30, 2030. It compares RC118/RC148 combinations to Tislelizumab plus CAPOX as first-line therapy for HER2-negative, claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma.
Primary source
ClinicalTrials.gov registry record, November 13, 2026
RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
Read the source: RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation